We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pall Corporation Acquires Molecular Diagnostics Manufacturer GeneSystems

By LabMedica International staff writers
Posted on 03 Oct 2008
Pall Corp. More...
(East Hill, NY, USA), a global leader in filtration, separation, and purification, has purchased GeneSystems (Bruz, France), a privately held biotechnology company that has developed a unique, easy-to-use, and cost-effective molecular diagnostics platform.

The acquisition of GeneSystems with its patented approach to rapid microbiologic detection equipment and disposables expands Pall's total fluid management (TFM) capabilities in the US$1 billion biopharmaceuticals process monitoring market. The acquisition also presents Pall with new opportunities in its environmental, food, and beverage and water markets.

Process monitoring includes the analytic tests required during biopharmaceuticals manufacturing for environmental monitoring, in-process control testing, and finished product release testing. These tests are receiving increased regulatory scrutiny and support under initiatives such as process analytic technology (PAT).

Founded in 2000, GeneSystems quickly gained market recognition for its quantitative Legionella diagnostic platform. Since its first product arrived on the market in 2004, GeneSystems has developed systems for the rapid and precise diagnosis of a range of pathogens, including food safety testing focused on Escherichia coli. These systems employ advanced sample preparation methods and real-time polymerase chain reaction (PCR) technology to enable fast and high throughput along with high reproducibility analysis of multiple DNA targets. Real-time PCR detects small quantities of specific microorganisms and provides results within hours.

"We are excited by this acquisition and the increased opportunities it presents for our pharmaceutical, biotechnology, environmental monitoring, quality control, and diagnostics programs,” said Eric Krasnoff, Pall Corporation chairman and CEO. "Customers seek better tools for rapid testing and process monitoring. GeneSystems expands our ability to provide total fluid management to meet customer's raw materials, production, testing, and environmental requirements. GeneSystems' unique technologies complement Pall's markets and global reach.”

"It is wonderful to join Pall and have the opportunity to expand on a global scale the very significant customer advantages that our team has achieved, diligently and creatively, during the last few years,” said Darryl Spurling, CEO of GeneSystems.

Pall Corp. is a global leader in the rapidly growing field of filtration, separation, and purification. Pall is organized into two businesses: life sciences and industrial. These businesses provide products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation, and broad industrial markets. The company has extensive operations around worldwide.

Related Links:
Pall Corp
GeneSystems


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.